z-logo
Premium
Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission—A cross‐sectional study
Author(s) -
Roussel Aphaia,
Delbet JeanDaniel,
Micheland Laurianne,
Deschênes Georges,
Decramer Stephane,
Ulinski Tim
Publication year - 2019
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.14912
Subject(s) - medicine , nephrotic syndrome , quality of life (healthcare) , observational study , rituximab , cross sectional study , nephrology , population , pediatrics , nursing , environmental health , pathology , lymphoma
Aim Severe forms of idiopathic nephrotic syndrome (INS) require immunosuppressive therapy: oral treatment or intravenous therapy (rituximab, RTX). The main objective was to describe quality of life (QOL) in these specific patients. Methods Cross‐sectional, multicentre, observational study analysed QOL using a standardised questionnaire in children from 7 to 17 years, with a steroid‐dependent or steroid‐resistant INS in stable remission. The questionnaire consisted of 30 questions concerning physical and emotional well‐being, self‐esteem, family, friends, school and disease resulting in a global score of 0‐100. Results A total of 110 patients with a mean age of 11.6 years from three French paediatric nephrology centres were included. A total of 71 patients had oral immunosuppressive treatment, 27 had RTX, and 12 had both. 13.6% of patients had a steroid‐resistant INS. The mean number of relapses was 5.8. Seventy‐eight patients answered the questionnaire. The global score in the whole study population was 74.7; 72.6 in the RTX group, 76.2 in the oral drugs group, ( P  = 0.49). The results of sub‐dimension ‘school’ were statistically lower in RTX group (61.6 ± 19.5) compared with oral drugs group (71.4 ± 16; P  = 0.02). Conclusion Global QOL score was high in ‘difficult‐to‐treat’ patients with INS in stable remission on oral immunosuppressive or RTX treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here